Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04749459 · ClinicalTrials.gov registry record · NA
Sun Protection Factor (SPF) Determination of Two Sunscreen-Containing Lip Balms
A NA study of Sunscreening Agents, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- NA
- Development phase
- 14
- Enrollment target
- 1
- Study location
NCT04749459: Completed NA study of Sunscreening Agents, sponsored by GlaxoSmithKline.
NCT04749459 is a NA study of Sunscreening Agents that has completed, run by GlaxoSmithKline. The registered enrollment target is 14 participants, below the 80-participant average among 21 other Sunscreening Agents trials with a reported enrollment target (82% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04749459, a NA study of Sunscreening Agents, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- NA
- Development phase
- 14 participants
- Enrollment target
- 1
- Study location
Study Summary
The aim of this study is to determine the SPF of two test materials ChapStick Moisturizer, Classic Flavor and ChapStick Moisturizer, Strawberry Flavor using the methodology described in the International Standard Test Method. This static methodology also meets the requirements of the Australia/New Zealand standard.
Primary Outcome
Arithmetic mean of all valid SPFi values of each product on each participant was calculated from the individual Minimal Erythemal Dose (MED) on product treated (MEDp) test sites in relation to unprotected (MEDu) test sites 16-24 hrs after exposure to UVR. SPFi = MEDp/MEDu. No inferential statistical analysis was performed for this outcome. The MED is defined as the lowest dose of UVR that produces the first perceptible unambiguous erythema with defined borders appearing over most of the field of
Conditions Studied
Interventions
- DRUG ChapStick Moisturizer, Strawberry Flavor
- DRUG ChapStick Moisturizer, Classic Flavor
- DRUG ISO 24444:2010 P2 Standard Reference Sunscreen
Study Locations (1)
New Jersey
- GSK Investigational Site - Fairfield
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2021-03-03 |
| Est. Completion | 2021-03-31 |
| Phase | NA |
What the finished NCT04749459 record still lists
NCT04749459 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 80-participant average among 21 other Sunscreening Agents trials with a reported enrollment target (82% lower).
The record links to 1 condition, with Sunscreening Agents appearing as the primary indexed condition, and to 3 interventions - of which ChapStick Moisturizer, Strawberry Flavor is the first listed.
NCT04749459 reports a single indexed study location in New Jersey.
Frequently Asked Questions
What is clinical trial NCT04749459 about?
NCT04749459 is a clinical study titled "Sun Protection Factor (SPF) Determination of Two Sunscreen-Containing Lip Balms". The aim of this study is to determine the SPF of two test materials ChapStick Moisturizer, Classic Flavor and ChapStick Moisturizer, Strawberry Flavor using the methodology described in the International Standard Test Method. This static methodology also meets the requirements of the Australia/New Z...
What is the current status of trial NCT04749459?
This trial is currently completed. It is a NA study. The enrollment target is 14 participants. The study started on 2021-03-03. Estimated completion is 2021-03-31.
What conditions does trial NCT04749459 study?
This clinical trial studies the following conditions: Sunscreening Agents.
What interventions are being tested in trial NCT04749459?
The interventions under investigation include: ChapStick Moisturizer, Strawberry Flavor (DRUG), ChapStick Moisturizer, Classic Flavor (DRUG), ISO 24444:2010 P2 Standard Reference Sunscreen (DRUG).
Who is sponsoring clinical trial NCT04749459?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04749459 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sunscreening Agents
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04749459's enrollment target sits among peer trials
14 10th of 21 higher than 11 of 21 other Sunscreening Agents trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Sunscreening Agents trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Impact of Sunscreen Dispensers in Parks Visited by Teenagers
ACTIVE NOT RECRUITING · NA
-
Clinical Study to Evaluate the Sun Protection Factor (SPF) of Three Sunscreen Products
COMPLETED · NA
-
To Assess the Safety of a Sunscreen Product
COMPLETED · NA
-
Evaluation of Sunscreen During Exercise Under Conditions of Profuse Sweating (821/2016)
COMPLETED · NA
-
Sun Protection Factor Assay (SPF Assay 204/2016)
COMPLETED · NA
-
18794 - Human Photo Toxicity Test
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy